BJDX — Bluejay Diagnostics Income Statement
0.000.00%
- $2.87m
- -$1.42m
Annual income statement for Bluejay Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.249 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.049 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.09 | 3.23 | 9.8 | 10.3 | 7.17 |
Operating Profit | -1.09 | -3.23 | -9.56 | -10.3 | -7.17 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.16 | -3.49 | -9.3 | -9.95 | -7.72 |
Net Income After Taxes | -1.16 | -3.49 | -9.3 | -9.95 | -7.72 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.16 | -3.49 | -9.3 | -9.95 | -7.72 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.16 | -3.49 | -9.3 | -9.95 | -20.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -797 | -1,390 | -3,595 | -3,631 | -114 |
Dividends per Share |